Peritia employs diverse R & D technologies to establish clinical development paths for biopharmaceuticals as well as diagnostic solutions for some of the most serious diseases including COVID-19.
The foundation of our approach is built on a robust regulatory science that is aimed at mitigation of risks from a clinical safety and efficacy perspective, different from the conventional high-risk, high-cost R&D models. Through collaborative partnerships, we seek to bring diagnostics and life-saving therapies that are accessible and affordable to patients.
TECHNOLOGY AND SOLUTIONS
Development and integration of analytical technologies and biological assays for structural and functional characterization of highly heterogeneous drugs and biological molecules.
Regulatory science based solutions that involve implementing a framework based on the integration of multiple synergistic analytical and functional measurements to establish robust correlations between i) the critical structural attributes of the drug ii) the process conditions and the product attributes and iii) the product attributes and appropriate readouts capturing the drug safety and efficacy profiles.
WHO WE ARE
We are a team of experienced individuals from world class institutions including: Harvard, MIT, Johns Hopkins, Duke, and Columbia. We bring unique cross-functional expertise in the following fields:
Data science and machine learning
Structure-guided drug design
Development and integration of sophisticated data analytical technologies
Upstream and downstream processes for biopharmaceutical production
In vitro and In vivo pre-clinical assay development
Diagnostics solutions for diseases including COVID-19